Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study

Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum

(2022) Emi Ishikawa et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

(2022) Hayato Yokota et al.   INVESTIGATIONAL NEW DRUGS

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

(2022) René J. Boosman et al.   PHARMACEUTICAL RESEARCH

EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

(2021) Nicolas Joly-Tonetti et al.   BMC CANCER

Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats

(2021) Yumi Harada et al.   BIOMEDICINE & PHARMACOTHERAPY

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism

(2021) Mohammed A. S. Abourehab et al.   MOLECULES

Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase® the WHO Global Database of Individual Case Safety Reports

(2021) Alexandre Crosnier et al.   Cancers

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

(2020) Karthick Vishwanathan et al.   Pharmacology Research & Perspectives

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Introns as Gene Regulators: A Brick on the Accelerator

(2019) Alan B. Rose   Frontiers in Genetics

Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice

(2019) Aya Hasan Al-Shammari et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Effects of Pharmacokinetics-related Genetic Polymorphisms on the Side Effect Profile of Afatinib in Patients with Non-Small Cell Lung Cancer

(2019) Hideki Hayashi et al.   LUNG CANCER

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

(2019) Stéphanie van Hoppe et al.   PHARMACOLOGICAL RESEARCH

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

(2018) Chihiro Endo-Tsukude et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

(2018) Chia‐Yu Chu et al.   ONCOLOGIST

Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs

(2018) Fusao Komada   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis

(2018) Lina Tang et al.   OncoTargets and Therapy

Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer

(2018) Carlos Fernandez-Teruel et al.   CLINICAL PHARMACOKINETICS

Hypoalbuminemia: Pathogenesis and Clinical Significance

(2018) Peter B. Soeters et al.   JOURNAL OF PARENTERAL AND ENTERAL NUTRITION

Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study

(2017) Hongyun Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters

(2016) Y Ma et al.   PHARMACOGENOMICS JOURNAL

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients

(2016) Yunfeng Ruan et al.   Scientific Reports

High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors

(2015) Sayed-Mohammad Hasheminasab et al.   PHARMACOGENOMICS

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

(2014) Huixin Yu et al.   CLINICAL PHARMACOKINETICS

EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity

(2012) Elena Galvani et al.   Future Oncology

Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal Disease

(2010) H Sun et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS